News | February 22, 2010

Complimentary Atrial Fibrillation Symposium is March 13 at ACC

February 22, 2010 – The session “The Future is Now: Changing Paradigms in Atrial Fibrillation (AF) Management,” will take place 8 a.m. to noon Saturday, March 13 in Atlanta, Ga., in room A301, Georgia World Congress Center.

The complimentary symposium will address atrial fibrillation (AF) from a multifaceted, multidisciplinary approach. Participants will benefit from first-rate knowledge of the guidelines and synopses of cutting-edge developments by the world's leading experts in AF. The program will examine variations among clinicians in these settings, looking at both gaps in knowledge of and adherence to current guidelines as it relates to the future of AF care and its changing climate within the EP and cardiology community.

Participants will benefit from knowledge of the guidelines and synopses of cutting edge developments by some of the world's leading experts in AF. Areas of focus will include: anticoagulation and stroke prevention; cardioversion; heart failure in AF; appropriate selection and endpoints for anti-arrhythmic drug therapy; and patient selection and techniques surrounding catheter ablation to treat AF.

Presenters include Eric N. Prystowsky, M.D., FHRS,?The Care Group LLC; Philip B. Gorelick, M.D., MPH, University of Illinois College of Medicine at Chicago; Jonathan L. Halperin, M.D.,?Mt. Sinai Medical Center; Peter R. Kowey, M.D., FHRS,?Main Line Arrhythmia and Cardiology Consultants at Lankenau Hospital; and Francis E. Marchlinski, M.D., FHRS,?Hospital of the University of Pennsylvania

For more information: http://hrsonline.org/Education/Courses/AFSymp10/

Related Content

Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins. The future of CRM device technology.

Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins.

Feature | EP Lab | November 11, 2019 | Hrishikesh Kadam
Cardiac rhythm management (CRM) devices in use today are evolving to raise the bar beyond monitoring and managing car
A comparison between the EPstar 2F and 6F catheters from Baylis. Electrophysiology catheters. EP lab

A comparison between the EPstar 2F and 6F catheters from Baylis.

News | EP Lab | October 31, 2019
October 31, 2019 — Baylis Medical announced the first North American use of its EPstar Fixed...
New Study Shows Chronic Epilepsy Associated With Marker of Cardiac Electrical Instability
News | EP Lab | October 24, 2019
LivaNova PLC announced the publication of a new study in Neurology, which suggests that chronic epilepsy may be...
Lenox Hill Hospital Opens New Heart Rhythm Center
News | EP Lab | August 27, 2019
Lenox Hill Hospital (New York, N.Y.) has established a brand new Heart Rhythm Center dedicated to the treatment of...
Damaged Hearts Rewired With Nanotube Fibers

Researchers at Texas Heart Institute and Rice University have confirmed that flexible, conductive fibers made of carbon nanotubes can bridge damaged tissue to deliver electrical signals and keep hearts beating despite congestive heart failure or dilated cardiomyopathy or after a heart attack. Image courtesy of Texas Heart Institute.

News | EP Lab | August 15, 2019
Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the...
Cardiac Device Complications Vary Widely Among Hospitals
News | EP Lab | July 31, 2019
The chances of patients experiencing complications after having a cardiac device implanted vary according to where they...
A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 

News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] Th
Studies Find Race and Gender Disparities in Implantable Heart Devices
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, includ
Overlay Init